Content:
Cholagogues, Cholelitholytics & Hepatic Protectors
Content on this page:
Cholagogues, Cholelitholytics & Hepatic Protectors
Corticosteroid Hormones
Supplements & Adjuvant Therapy
Disclaimer
Related MIMS Drugs
Content on this page:
Cholagogues, Cholelitholytics & Hepatic Protectors
Corticosteroid Hormones
Supplements & Adjuvant Therapy
Disclaimer
Related MIMS Drugs
Cholagogues, Cholelitholytics & Hepatic Protectors
Drug | Dosage | Remarks |
Branched-chain amino acids (L-isoleucine, L-leucine, L-valine)1 |
4.15 g sachet, take 1 sachet with a glass of water PO 8 hourly after meals | Adverse Reactions
|
L-ornithine-L-aspartate | 3 g or 5 g sachet, take 1-2 sachet dissolved in liquid PO up to 8 hourly or 20 g/day IV infusion | Adverse Reactions
|
Metadoxine | 1,000 mg PO 24 hourly or 500 mg PO 8 hourly |
Special Instructions
|
Phospholipids1 (Essential phospholipids) |
600 mg PO 8 hourly | Adverse Reactions
|
Silymarin1 | 150-200 mg PO 12-24 hourly or Initially for severe disease: 140 mg PO 8 hourly for 3-6 months Maintenance dose: 70 mg PO 8 hourly or 140 mg PO 12 hourly |
Adverse Reactions
|
Ursodeoxycholic acid |
Individualize dose | Adverse Reactions
|
Corticosteroid Hormones
Drug | Dosage | Remarks |
Betamethasone | 1.5-5 mg PO 24 hourly for 1-3 weeks, then reduce dose until effective minimum dose is reached |
Adverse Reactions
|
Supplements & Adjuvant Therapy
Drug | Dosage | Remarks |
S-adenosyl-L-methionine | 400-1,200 mg PO 24 hourly in divided doses for 6 months |
Special Instructions
|
Disclaimer
All dosage recommendations are for non-elderly adults with normal renal and hepatic function unless otherwise stated.
Not all products are available or approved for above use in all countries.
Products listed in the Drug Summary are based on indications stated in the locally approved product monographs.
Please refer to local product monographs in Related MIMS Drugs for country-specific prescribing information.
Not all products are available or approved for above use in all countries.
Products listed in the Drug Summary are based on indications stated in the locally approved product monographs.
Please refer to local product monographs in Related MIMS Drugs for country-specific prescribing information.